Document is current
Any future updates will be listed below
-
Authors
Boman, Sol Erika
Mulliqi, Nita
Blilie, Anders
Ji, Xiaoyi
Szolnoky, Kelvin
Gudlaugsson, Einar
Janssen, Emiel A.M.
Kjosavik, Svein R.
Asenjo, José
Gambacorta, Marcello
Libretti, Paolo
Braun, Marcin
Kordek, Radzislaw
Łowicki, Roman
Hotakainen, Kristina
Väre, Päivi
Pedersen, Bodil Ginnerup
Sørensen, Karina Dalsgaard
Ulhøi, Benedicte Parm
Egevad, Lars
Kartasalo, Kimmo
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 26 April 2025
Accepted: 4 May 2026
First Online: 13 May 2026
Declarations
:
: N.M., L.E., and K.K. are shareholders of Clinsight AB.
: This study included data gathered in one or more collection rounds at participating international sites between 2012 and 2024. All datasets were de-identified at their respective sites and subsequently transferred to Karolinska Institutet in an anonymized format. This study complies with the Helsinki Declaration. The patient sample collection was approved by the Stockholm Regional Ethics Committee (permits 2012/572 − 31/1, 2012/438 − 31/3, and 2018/845 − 32), the Swedish Ethical Review Authority (permit 2019–05220), and the Regional Committee for Medical and Health Research Ethics in Western Norway (permits REC/Vest 80924, REK 2017/71). Informed consent was obtained from patients in the Swedish dataset and was waived for other data cohorts due to the use of de-identified prostate specimens in a retrospective setting. Patient involvement in this study was supported by the Swedish Prostate Cancer Society.
